AstraZeneca announces encouraging results from OSTRO trial
AstraZeneca (AZN) reported positive data from its Phase III OSTRO trial pertaining Fasenra. The study met both its co-primary endpoints in patients with chronic rhinosinusitis with nasal polyps. The safety profile and tolerability of the drug candidate in this trial were in line with the known profile of the medicine.
OSTRO is a randomised, double-blinded, multi-centre, parallel-group, 56-week Phase III trial. It assessed the efficacy and safety of Fasenra compared to placebo in patients with nasal polyposis. The trial involved participants, regardless of blood eosinophil count